On March 14, 2024, Cell BioTech Co. Ltd. (KOSDAQ: CBT/049960) announced that all probiotic strains included in NBL probiotics have received GRAS (Generally Recognized As Safe) status from the U.S. Food and Drug Administration (FDA). This status affirms the safety of the microorganisms for use in food products and dietary supplements.
Patented Probiotic Strains from Cell Biotech Approved by the FDA:
- Streptococcus thermophilus CBT ST3
- Lactobacillus acidophilus CBT LA1
- Lactobacillus rhamnosus CBT LR5
- Bifidobacterium longum CBT BG7
- Bifidobacterium bifidum CBT BF3
- Lactobacillus casei CBT LC5
- Lactobacillus rhamnosus CBT LR5
- Bifidobacterium plantarum CBT LP3
- Bifidobacterium lactis CBT BL3
FDA Nostrification — A Guarantee of Safety
GRAS certification by the FDA is one of the strictest global safety protocols, confirming that the microorganisms used in food products are safe for human consumption. Receiving the “No Objection” notice from the FDA involves an extensive evaluation process requiring substantial scientific data to demonstrate the safety of the substance for its intended use.
What This Means for Consumers:
- Safety Guarantee: GRAS status ensures that independent FDA experts have recognized the probiotic strains as safe for use in food products and supplements.
- Scientific Validation: FDA acknowledges the research conducted to prove the safety and effectiveness of probiotics, ensuring their high quality and safety for consumers.
Cell Biotech continues its commitment to advancing probiotic research and development, maintaining its position as a global leader in product safety and quality.
Comment from Cell BioTech Co. Ltd. CEO:
“We are very pleased to have taken this crucial step in ensuring the long-term growth of our business in the U.S. Despite the presence of many probiotic ingredient suppliers, the distinct advantages of our patented technology and quality control methods provide unmatched scalability and reliability for leading consumer brands. Obtaining GRAS status from the FDA was essential for earning trust and loyalty from new customers in the U.S. as we expand globally,” said Dr. Myun Joon Chung, CEO of Cell BioTech Co. Ltd.
Source: fox16.com
